Agtc Genomics Sdn. Bhd.

What Agtc Genomics Sdn. Bhd. does

AGTC Genomics Sdn. Bhd. is a Kuala Lumpur-based precision genomics company founded in 2021 that operates a CAP-accredited and ISO15189/ISO17025-certified clinical laboratory delivering cancer genomics, clinical genomics, and research sequencing services across Malaysia. The portfolio comprises 14 branded clinical diagnostic products spanning hereditary cancer screening (CancerRiskDx), multi-cancer early detection (CancerScreenDx), comprehensive genomic profiling (OncoDx), liquid biopsy (LiquidDx), MRD monitoring (CancerTRACE), whole genome and exome sequencing (NovaDx, InsightDx), carrier and newborn screening (HorizonDx, OrigenDx), rare disease diagnostics (OdysseyDx), pharmacogenomics (PharmPGx), polygenic risk scoring (ContinuumDx), and HLA typing for transplant (HLA-Dx), supported by 14 research services covering WGS, WES, single-cell, metagenomic, methylation, and bioinformatics analysis on Illumina NGS platforms.

The business operates a B2B enterprise sales model with direct engagement of oncologists, pathologists, hematologists, geneticists, and clinical teams at hospitals, clinics, laboratories, universities, and government agencies, alongside a direct-to-consumer online ordering portal and mobile phlebotomy services. Revenue is generated primarily through one-time clinical test fees, professional services for research clients, and recurring collaboration arrangements with pharmaceutical and biotech partners; pricing is quote-based and not publicly disclosed. The company has secured hospital reference partnerships with major Malaysian groups (Pantai, Columbia Asia, Prince Court, Thomson, Regency, UM Specialist Centre, Sunny), academic partnerships with Monash University and Sunway University, and government engagement with the Ministry of Health Malaysia, the Institute for Medical Research, the World Health Organization, and Bioeconomy Corporation, where it holds BioNexus status. The team is led by Founder and CEO Professor Dr. Leong Chee Onn (PhD, Harvard Fellow, FRSB, FRSC) and includes a Chief Technology Officer, Chief Marketing Officer, Chief Genetic Counsellor, Senior Full-Stack AI Engineer, and Senior Bioinformatician among 11–50 total staff.

Name

Agtc Genomics Sdn. Bhd.

Legal name

AGTC GENOMICS SDN BHD (1428365-D)

Website

https://agtcgenomics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

AGTC Genomics is a CAP-accredited Malaysian clinical genomics laboratory delivering cancer, clinical, and research genomic testing services to hospitals, clinicians, researchers, and pharmaceutical partners across Malaysia. The company offers 14 branded clinical diagnostic products and research sequencing services on Illumina NGS platforms.

Ownership category

akta.pro rank

Product category

Clinical Genomic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Clinical genomic testing
• Next generation sequencing
• Cancer genomics diagnostics
• Bioinformatics analysis services
• Hereditary disease screening

Headquarters

HQ city

Kuala Lumpur

HQ country

Malaysia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Genomic Testing Services: Laboratory-developed tests covering cancer genomics (hereditary screening, early detection, comprehensive profiling, liquid biopsy, MRD monitoring) and clinical genomics (whole genome sequencing, exome sequencing, carrier screening, newborn screening, rare disease diagnostics, pharmacogenomics, polygenic risk scores, HLA typing). Tests are processed in CAP-accredited and ISO15189 certified laboratory in Malaysia.
2. Research Services: Genomic sequencing services for research institutions and pharmaceutical companies including whole genome sequencing, whole exome sequencing, human genotyping arrays, COVID-19 sequencing, de novo sequencing, transcriptome sequencing, mRNA sequencing, microRNA sequencing, single cell sequencing, metagenomic sequencing, bisulfite sequencing, methylation microarray, and bioinformatics analysis.
3. Collaborations and Partnerships: Strategic partnerships with life sciences organizations, biotech and pharma companies for drug discovery, clinical trial support, biomarker discovery, and population health programs.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

AGTC Genomics operates a CAP-accredited and ISO15189/ISO17025-certified clinical laboratory in Kuala Lumpur that delivers laboratory-developed genomic tests using Next Generation Sequencing, microarray, and AI-powered bioinformatics. The company sells cancer genomics, clinical genomics, and research sequencing services to healthcare providers, patients, hospitals, and research institutions in Malaysia and Southeast Asia.

Product overview

AGTC Genomics is a precision genomics company offering a multi-category platform of clinical diagnostic products and research services. The portfolio spans three main areas: Cancer Genomics products including CancerRiskDx™ (hereditary cancer screening), CancerScreenDx™ (multi-cancer early detection), OncoDx™ (comprehensive genomic profiling), LiquidDx™ (liquid biopsy), and CancerTRACE™ MRD (recurrence monitoring); Clinical Genomics products including NovaDx™ (whole genome sequencing), InsightDx™ (whole exome sequencing), HorizonDx™ (carrier screening), OrigenDx™ (newborn screening), OdysseyDx™ (rare disease), PharmPGx™ (pharmacogenomics), ContinuumDx™ (polygenic risk), and HLA-Dx™ (transplant typing); and Research Services including WGS, WES, genotyping arrays, COVID-19 sequencing, de novo sequencing, transcriptome sequencing, single cell sequencing, metagenomic sequencing, bisulfite sequencing, methylation microarrays, and bioinformatics analysis. The company integrates Next Generation Sequencing (NGS), microarray, and big data analytics platforms to deliver clinical and research genomic testing services.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• WGS can solve up to 30% of cases that other testing methods miss for patients with inconclusive results from prior testing
• +5 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Institute for Medical Research (IMR)coreStrategic or Co-development Partner · 18 June 2024AGTC Genomics and IMR co-hosted a landmark technical workshop on 16S Microbiome Analysis, demonstrating collaborative efforts in advancing microbiome research capabilities and training healthcare professionals in genomic analysis techniques.
• BioNexus Partners LaboratoriescoreStrategic or Co-development PartnerAGTC Genomics has strengthened engagement with BioNexus Partner Laboratories to advance translational genomics for Malaysia's bioeconomy. This partnership focuses on collaborative efforts to accelerate the adoption of precision medicine and genomic testing across healthcare institutions in Malaysia.
• Ministry of Health MalaysiacoreStrategic or Co-development PartnerAGTC Genomics held strategic discussions with the Ministry of Health Malaysia to advance precision medicine in Malaysia. This engagement aims to support government healthcare initiatives and integrate genomic testing into national healthcare strategies.
• Sunny Medical CentreminorStrategic or Co-development PartnerHealthcare provider partnership for genomic testing services, serving as a reference hospital partner for AGTC's diagnostic services.
• Pantai HospitalminorStrategic or Co-development PartnerHealthcare provider partnership for genomic testing services, one of the major hospital networks in Malaysia.
• Columbia Asia HospitalminorStrategic or Co-development PartnerHealthcare provider partnership for genomic testing services, part of the Columbia Asia hospital network in Southeast Asia.
• Prince Court Medical CentreminorStrategic or Co-development PartnerHealthcare provider partnership for genomic testing services, a premium medical centre in Kuala Lumpur.
• Thomson Medical CentreminorStrategic or Co-development PartnerHealthcare provider partnership for genomic testing services, a hospital group focused on women's and children's health.
• Monash UniversityminorStrategic or Co-development PartnerAcademic partnership for research collaboration, education, and knowledge sharing in genomics and precision medicine.
• Sunway UniversityminorStrategic or Co-development PartnerAcademic partnership for research collaboration and education in genomics and related fields.
• World Health Organization (WHO)coreStrategic or Co-development PartnerInternational health organization partnership demonstrating alignment with global health standards and initiatives in precision medicine and genomics.
• Bioeconomy CorporationcoreStrategic or Co-development PartnerGovernment agency supporting biotechnology companies in Malaysia. AGTC Genomics holds Bionexus status, indicating strategic importance to Malaysia's bioeconomy development.

Scale indicators7 records

Recent moves6 records

Expansion highlights12 records

Direct peers

• Strand Life Sciences: India-based precision medicine company combining clinical genomics (hereditary cancer, reproductive health, rare disease) with proprietary bioinformatics. Comparable to AGTC across clinical testing menu and bioinformatics emphasis.
• MedGenome: India-based clinical genomics and bioinformatics company offering hereditary cancer screening, carrier screening, NIPT, and oncology NGS panels. Direct peer in the South/Southeast Asian clinical genomics market with overlapping product categories.
• Macrogen: Korea-based clinical and research genomics lab offering WGS, WES, microarray, and clinical NGS testing across Asia. Comparable in scale and service mix to AGTC and a likely regional competitor for hospital and pharma NGS contracts.
• Novogene: Asia-Pacific NGS services provider with comprehensive WGS/WES, single cell, transcriptome, and bioinformatics offerings for academic and pharma clients. Closely comparable to AGTC's research services arm and similarly competes for Southeast Asian sequencing projects.

Broad incumbents

• Neogenomics: US-based clinical cancer genomics laboratory offering CGP, hereditary cancer, hematology, and MRD testing. Comparable in clinical menu and hospital channel, though at significantly larger scale than AGTC.
• BGI Genomics: China-headquartered global genomics powerhouse offering clinical NGS testing, WGS/WES, reproductive health, and cancer profiling, plus proprietary sequencing platforms. AGTC competes against BGI for Asian-region clinical and research sequencing volume and uses competing Illumina technology.
• Foundation Medicine: US-based comprehensive genomic profiling (CGP) provider for oncology, owned by Roche. Direct comparator for AGTC's OncoDx CGP product in terms of assay breadth and clinical actionability claims.

Emerging players

• Personalis: US-based NGS-focused oncology testing company offering comprehensive genomic profiling and MRD solutions (NeXT Personal). Relevant emerging competitor for AGTC's CGP and MRD product lines.
• Guardant Health: US-based liquid biopsy and comprehensive genomic profiling leader whose ctDNA technology underpins products like LiquidDx and CancerTRACE in AGTC's portfolio. Relevant competitor and category-defining reference for AGTC's liquid biopsy and MRD offerings.
• Natera: US-based cell-free DNA testing company with strength in reproductive health, oncology recurrence monitoring (Signatera MRD), and organ transplant monitoring. Comparable to AGTC's CancerTRACE MRD and HLA-Dx offerings in technology and clinical positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/WixStudio
• YouTubeyoutube.com/channel/UCpWSU_7FbeyCMc4SPHCCLwg
• Facebookfacebook.com/agtcgenomics
• LinkedInlinkedin.com/company/agtc-genomics-sdn-bhd
• Instagraminstagram.com/agtcgenomics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agtc Genomics Sdn. Bhd.